8-K: Dyadic International Secures CEPI Funding to Accelerate Vaccine Development Using C1 Technology

Dyadic International receives a $4.5 million funding award from CEPI to explore using its C1 fungus technology for faster and more cost-effective protein-based vaccine development.

Summary

• Dyadic International has been awarded $4.5 million in funding from CEPI to advance the development of protein-based vaccines using its C1 fungus technology.
• The funding will support proof-of-concept research conducted by Fondazione Biotecnopolo di Siena (FBS) to assess the C1 platform's potential as a faster and more cost-effective alternative to mammalian cell-based antigen production.
• The C1 fungus cell line could potentially produce vaccine proteins in just 35 days, significantly reducing the development timeline compared to the four to six months required for mammalian cell lines.
• The C1 technology aims to produce large quantities of proteins with reduced reliance on complex and expensive biopharmaceutical facilities, making it suitable for regional manufacturing and improving vaccine access in lowand middle-income countries.
• The CEPI-FBS partnership aligns with the 100 Days Mission, a G7 and G20 initiative to accelerate vaccine development timelines in response to pandemic threats.

Sentiment

Score: 8

Explanation: The announcement is positive due to the significant funding from CEPI, the potential for faster vaccine development, and the focus on global health security. The collaboration with FBS further strengthens the positive outlook.

Positives

• CEPI funding validates Dyadic's C1 platform for vaccine development.
• The C1 technology has the potential to significantly reduce vaccine development timelines and costs.
• The technology could improve vaccine access in lowand middle-income countries.
• The collaboration with CEPI and FBS strengthens Dyadic's position in the global health security landscape.

Risks

• The success of the project depends on the C1 fungus producing antigens comparable in structure and immunogenicity to those produced in mammalian cells.
• Market and regulatory acceptance of the microbial protein production platforms and other technologies is not guaranteed.
• Competition from alternative technologies could impact the adoption of the C1 platform.

Future Outlook

The next phase of the project will focus on selecting an antigen from a pathogen of interest to CEPI to demonstrate a reduced timeline for vaccine development if the initial research is successful.

Management Comments

• Mark Emalfarb, Dyadic's CEO, stated that the funding accelerates C1's development for pandemic preparedness and aims to prevent zoonotic outbreaks and strengthen global health security.
• Prof. Rino Rappuoli, Scientific Director FBS, said there is a huge need for new technology platforms that can deliver vaccines that can be produced rapidly, that can be affordable for every person of the planet, that can easily be stored in refrigerators, and that can be rapidly scaled to billions of doses.

Industry Context

This announcement highlights the ongoing efforts to improve vaccine development and manufacturing processes, particularly in response to the need for rapid and scalable solutions for emerging infectious diseases. CEPI's investment in innovative technologies like Dyadic's C1 platform reflects the industry's focus on pandemic preparedness and global health security.

Comparison to Industry Standards

• Traditional mammalian cell-based vaccine production typically takes 4-6 months to establish a stable cell line, while Dyadic's C1 technology aims to reduce this to 35 days.
• The C1 technology aims to offer a more affordable and scalable alternative to mammalian cell cultures, potentially enabling regional manufacturing and improved access in lowand middle-income countries.
• Companies like Sanofi and GSK also invest heavily in vaccine development, but Dyadic's fungal-based approach offers a unique alternative to traditional methods.

Stakeholder Impact

• Shareholders may benefit from the increased valuation and potential revenue streams associated with the C1 technology.
• Employees may benefit from the expansion of research and development activities.
• The technology could lead to faster and more affordable vaccines, benefiting global health security.

Next Steps

• Researchers will compare the antigen produced by the C1 fungus to those produced in mammalian cells to assess comparability in structure and immunogenicity.
• If successful, the next phase will focus on selecting an antigen from a pathogen of interest to CEPI to demonstrate a reduced timeline for vaccine development.

Key Dates

Keywords

vaccine development, C1 technology, CEPI, protein production, Dyadic International, antigen, pandemic preparedness